Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
|
BRAF V600E • KRAS wild-type • KRAS exon 2 mutation • KRAS exon 2 wild-type
|
futuximab/modotuximab (S95026) • S95029 • Sym021